A study published in the International Journal of Molecular Sciences reported that coagulation factor II receptor expression was higher in ovarian cancer tissues than in normal ovarian and fallopian tube controls, based on analyses of public transcriptional datasets. Elevated gene expressions were observed across multiple ovarian cancer subtypes.
Protein expressions were assessed in patient-derived samples using flow cytometry, immunofluorescence, and immunohistochemistry. Coagulation factor II receptor was detected in ascites-derived ovarian cancer cells and in high-grade serous ovarian cancer tissues. Immunohistochemistry showed higher protein expression in metastatic samples compared with primary tumors, and higher expression in chemotherapy-resistant samples compared with chemotherapy-sensitive samples. In Kaplan–Meier analysis, patients with lower coagulation factor II receptor protein expression had longer progression-free survival than patients with higher expression, while overall survival did not differ significantly between the groups.
Functional studies using small interfering RNA in ovarian cancer cell lines showed that coagulation factor II receptor knockdown reduced motility, invasion, spheroid formation, and metabolic activity. Knockdown was also associated with increased sensitivity to carboplatin.
These results point to a potential use of coagulation factor II receptor in the development of standardized immunohistochemistry or immunoassay biomarker tests. Such assays could allow classification of patients by expression level for clinical decision-making, although further prospective studies would be needed to establish thresholds and evaluate performance in practice.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
